Experts related details of the creation of the ZF-UZ-VAC2001 coronavirus vaccine. According to the Ministry of Innovative Development, the ZF-UZ-VAC2001 vaccine against COVID-19 is a vaccine with an adjuvant of the COVID-19 protein subunit, developed by Anhui Zhifei Longcom Biopharmaceutical in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) and the Center of Advanced Technologies.
As a result of the direct participation of the Ministry of Innovative Development and the Center for Advanced Technologies in drug trials, as well as for the contribution to the clinical trial, Uzbekistan was recognized as a co-author of the vaccine.
“During the development of the ZF-UZ-VAC2001 vaccine, a technology was applied similar to the technologies for creating other recombinant vaccines, such as NVX-CoV2373 (Novavax), EpiVacCorona (Vector), etc. The ZF-UZ-VAC2001 vaccine was obtained biotechnologically by creating a recombinant protein NCP- RBD coronavirus SARS-CoV-2,” the statement said.
In response to this protein, the immune system produces antibodies to neutralize the virus.
This vaccine is given in three doses over two months.
The ZF-UZ-VAC2001 vaccine is made from a purified receptor-binding section of the coronavirus spike glycoprotein (NCP-RBD recombinant protein) expressed by recombinant CHO cells and the addition of an aluminum hydroxide adjuvant.
"The adjuvant is used to prevent respiratory diseases caused by the new coronavirus infection," the ministry concluded.
